Citations

Clear

7552 citation(s) found for "Ku, Matthew".

Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma
Cloyd, Jordan M. , Sarna, Angela, Arango, Matthew J. , Bates, Susan E. , Bloomston, Mark, Ferrone, Cristina R., Gambino, Patricia, Goenka, Ajit H. , Hall, William A. , Jayaraman, Shiva , Kambadakone, Avinash, Ko, Andrew , Kooby, David A. , Krishna, Somashekar G. , Larsson, Liliana, Massarweh, Nader N. , Mikhail, Sameh , Palta, Manisha , Petzel, Maria Q. B., Philip, P. A., Mina, Daniel Santa , Sohal, Davendra , Sundaresan, Tilak , Tsai, Susan, Vreeland, Timothy J. , Walston, Steve, Wo, Jennifer Y. , Snyder, Rebecca A. , He, Jin , Tsai, Susan , Krishna, Somashekar G , Santa Mina, Daniel , Bates, Susan E , Bhutani, Manoop S. , Chung, Vincent , Dotan, Efrat , Goodman, Karyn A. , He, Jing , Hogg, Melissa E. , Katz, Matthew H. G. , Khorana, Alok A. , Koay, Eugene J. , Lee, Richard T. , Maitra, Anirban , Muzaffar, Mahvish , O’Reilly, Eileen M. , Reyngold, Marsha , Turner, Kea L. , Washington, Mary Kay , Williams, Terence M. , Snyder, Rebecca A.

Mayo Clinic

JAMA Surgery | December 4, 2024 | Volume: 160 | Issue: 2 | Pages: 172

10.1001/jamasurg.2024.5191 | PMID 39630427 Get It

Importance Neoadjuvant therapy (NT) is an increasingly used treatment strategy for patients with localized pancreatic ductal adenocarcinoma (PDAC). Little research has been conducted on cancer care delivery during NT, and the standards for optimal delivery of NT have not been defined. Objective To develop consensus best practices for delivering NT to patients with localized PDAC. Design, Setting, and Participants This study used a modified Delphi approach consisting of 2 rounds of voting, and a series of virtual conferences (from October to December 2023) to reach expert consensus on candidate best practice statements generated from a systematic review of the literature and expert opinion. An interdisciplinary panel was formed including 47 North American experts from surgical, medical, and radiation oncology, radiology, pathology, gastroenterology, integrative oncology, anesthesia, pharmacy, nursing, cancer care delivery research, and nutrition as well as patient and caregiver stakeholders. Main Outcome and Measures Statements that reached 75% agreement or greater were included in final consensus statements. Results Of the 47 participating panel members, 27 (57.64%) were male, and the mean (SD) age was 47.6 (8.2) years. Physicians reported completing training a mean (SD) 14.6 (8.6) years prior and seeing a mean (SD) 110.6 (38.4) patients with PDAC annually; 35 (77.7%) were in academic practice. Final consensus was reached on 82 best practices for delivering NT. Of these, 38 statements focused on pre-NT practices, including diagnosis and staging (n = 15), evaluation and optimization (n = 20), and decision-making (n = 3); 29 statements defined best practices during NT, including initiation (n = 3), delivery of therapy (n = 8), restaging practices (n = 12), and management of complications during NT (n = 6); and 15 best practices were identified to guide treatment post-NT, focusing on surgery (n = 7), pathology (n = 4), and follow-up (n = 3). Conclusions Using a modified Delphi consensus technique, best practice guidelines were developed focusing on the optimal standards for delivering NT to patients with localized PDAC. Given the prognostic importance of completing multimodality therapy, efforts to standardize and optimize the delivery of NT represent an immediate opportunity to decrease care variation and improve outcomes for patients with PDAC. Future research should focus on validating and implementing best practice standards into clinical practice.
Medially Migrating Vestibular Schwannomas: A Review of 10 Cases
Brovold, Brooklyn L., Lohse, Christine M. , Lane, John I. , Breen, Joseph J., Carlson, Matthew L., Breen, Joseph L, Mehta, P. , Bathla, Girish , Breen, Joseph L., Gompel, Jamie J. Van , Carlson, Matthew L.

Mayo Clinic

Otology & Neurotology | December 4, 2024 | Volume: 46 | Issue: 1 | Pages: e41-e45

10.1097/mao.0000000000004381 | PMID 39627846 Get It

Objective To analyze cases of medial migration of vestibular schwannomas to propose an underlying mechanism. Study Design Retrospective chart review. Patients Ten patients from one institution with sporadic vestibular schwannomas that demonstrated medial migration toward the cerebellopontine angle on serial imaging were reviewed. Interventions Among the 10 patients studied, 8 patients underwent stereotactic radiosurgery and 2 were managed with wait-and-scan. All serial imaging was analyzed throughout follow-up. Main Outcome Measures Volumetric and linear measurements were used to assess vestibular schwannoma growth. The fundal fluid cap length was measured from the most lateral end of the neoplasm within the internal auditory canal to the medial end of the cochlea. Pure tone averages of 0.5, 1, 2, and 3 kHz, word recognition scores, and AAO-HNS hearing class were used to assess levels of hearing loss per patient. Results Tumor growth exhibited a positive correlation with medial migration. Of the 10 patients studied, 9 exhibited tumor volume growth from initial to most recent imaging. Median changes in tumor volumes and fundal fluid cap lengths from initial diagnosis to the most recent imaging regardless of intervention were 130 mm3 (range 1,400–2,970) and 2.8 mm (range 1.8–6.0), respectively. Migration was noted in 4 patients prior to any intervention, in 4 patients postradiosurgery, and in 2 patients before and after radiosurgery. Therefore, half of the tumors studied migrated before an intervention and half migrated postradiosurgery. No correlation of migration and hearing decline was observed. Conclusion Medial migration of vestibular schwannoma is associated with an increase in tumor volume, supporting a “tumor squeeze” mechanism within a conical internal auditory canal toward the wider porus acusticus and cerebellopontine angle.
Diagnosing a child presenting with symptoms suggesting Sjögren’s disease: a tool for clinical practice
Stern, Sara M , Basiaga, Matthew L. , Cha, Seunghee , Thatayatikom, Akaluck , Treemarcki, Erin , Randell, Rachel L. , Dizon, Brian , Appenzeller, Simone , Edens, Cuoghi , Orrock, Janet , Tiger, Sharon, Diianni, Jamie, Amoafo, Linda , Lieberman, Scott M. , Treemarcki, Erin B , Dizon, Brian L P , Orrock, Janet E , Randell, Rachel L , Stern, Sara

Mayo Clinic

Rheumatology | December 2, 2024 | Volume: 64 | Issue: 5 | Pages: 3039-3047

10.1093/rheumatology/keae640 | PMID 39673525 Get It

Abstract Objective Childhood SjD (cSjD) is a rare disease. There are no widely accepted diagnostic or classification criteria for cSjD. To fill this gap, members from the CARRA Sjögren Disease Workgroup and the International Childhood Sjögren Disease Workgroup created a clinical diagnostic algorithm. This study evaluated the accuracy of this algorithm using an international cohort of participants with clinician-diagnosed cSjD. Methods First, experts developed a cSjD diagnostic algorithm through a series of virtual workgroup meetings. Using the adult classification criteria as a framework, experts modified the algorithm through opinion and literature review. The group discussed and finalized each algorithm step by achieving majority rule. Then, R statistical software was used to evaluate each participant’s disease status in the diagnostic algorithm via an international cohort of 300 cSjD cases. Results The diagnostic algorithm has three distinct clinical pathways representing the key clinical presentation in cSjD: parotitis, extraglandular manifestations, and sicca symptoms. The algorithm showed an overall sensitivity of 75% in the population that had enough data to complete at least one pathway of the algorithm (n = 100 filtered out of 300). The parotitis (70%) and sicca pathways (82%) had the highest sensitivity, and the extraglandular pathway (52%) had the lowest. Conclusion As cSjD lacks a diagnostic strategy, this algorithm provides a clinical tool for evaluating children with cSjD-like symptoms. It performed well in an international cohort of cSjD, supporting the integration of this algorithm into clinical practice; however, its utility may be limited by low utilization of diagnostic testing in this population.
Intraoperative Tranexamic Acid in Radical Cystectomy: Impact on Bleeding, Thromboembolism, and Survival Outcomes
Ahmed, Mohamed E. , Andrews, Jack R. , Thapa, Prabin , Tyson, Mark D. , Khanna, Abhinav, Shah, Paras , Sharma, Vidit , Thompson, R. Houston, Boorjian, Stephen A. , Frank, Igor, Tollefson, Matthew K. , Karnes, R. Jeffrey , Reitano, Giuseppe , Mahmoud, Ahmed

Mayo Clinic

Journal of Urology | December 2, 2024 | Volume: 213 | Issue: 4 | Pages: 447-454

10.1097/ju.0000000000004358 | PMID 39621967 Get It

Implementing evidence‐based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024
Bryce, Alan H. , Beltran, Himisha , Hussain, Maha , Armstrong, Andrew J. , Calais, Jérémie , Dorff, Tanya B. , Gomella, Leonard G. , Higano, Celestia, Morris, David S. , Petrylak, Daniel P. , Reiter, Robert E. , Ryan, Charles J. , Sellinger, Scott B., Srinivas, Sandy, Taplin, Mary‐Ellen , Zhang, Tian , McKay, Rana R. , Koo, Phillip J. , Crawford, E. David , Armstrong, Andrew J , Dorff, Tanya , Morris, Michael J , Spratt, Daniel E , Tagawa, Scott T , Zhang, Tian , Bryce, Alan H , Hussain, Maha H A , Calais, Jeremie , Agarwal, Neeraj, Sartor, Oliver , Shore, Neal D. , Antonarakis, Emmanuel S. , Carducci, Michael A. , Efstathiou, Jason A. , Gleave, Martin , Higano, Celestia S. , Hope, Thomas A. , Iagaru, Andrei H. , Morgans, Alicia K. , Morris, David S., Morris, Michael J. , Rettig, Matthew B. , Spratt, Daniel E. , Tagawa, Scott T. , Yu, Evan Y.

Mayo Clinic

Cancer | December 1, 2024 | Volume: 131 | Issue: 1 | Pages: No page available

10.1002/cncr.35612 | PMID 39616467 Get It

AbstractCurrent US clinical practice guidelines for advanced prostate cancer management contain recommendations based on high‐level evidence from randomized controlled trials; however, these guidelines do not address the nuanced clinical questions that are unanswered by prospective trials but nonetheless encountered in day‐to‐day practice. To address these practical questions, the 2024 US Prostate Cancer Conference (USPCC 2024) was created to generate US‐focused expert clinical decision‐making guidance for circumstances in which level 1 evidence is lacking. At the second annual USPCC meeting (USPCC 2024), a multidisciplinary panel of experts convened to discuss ongoing clinical challenges related to 5 topic areas: biochemical recurrence; metastatic, castration‐sensitive prostate cancer; poly [ADP‐ribose] polymerase inhibitors; prostate‐specific membrane antigen radioligand therapy; and metastatic, castration‐resistant prostate cancer. Through a modified Delphi process, 34 consensus recommendations were developed and are intended to provide clinicians who manage prostate cancer with guidance related to the implementation of novel treatments and technologies. In this report, the authors review the areas of consensus identified by the USPCC 2024 experts and evaluate ongoing unmet needs regarding translational application of the current clinical evidence.
Cutibacterium acnes periprosthetic joint infections
Warne, Christopher N. , Ryan, Sean P. , Yu, Elizabeth , Osmon, Douglas R. , Berry, Daniel J., Abdel, Matthew P. , Berry, Daniel J. , Ryan, Sean , Abdel, Matthew P , Osmon, Douglas R , Berry, Daniel J , Berry, Daniel J.

Mayo Clinic

The Bone & Joint Journal | November 30, 2024 | Volume: 106-B | Issue: 12 | Pages: 1426-1430

10.1302/0301-620x.106b12.bjj-2024-0437.r1 | PMID 39615518 Get It

Aims Cutibacterium acnes ( C. acnes ; previously known as Propionibacterium acnes or P. acnes ) periprosthetic hip and knee infections are under-reported. While culture contamination with C. acnes occurs, true infections are important to recognize and treat. We sought to describe the demographics and treatment outcomes of patients with C. acnes periprosthetic joint infections (PJIs) of the hip and knee. Methods Patients with C. acnes PJI between January 2005 and December 2018 were retrospectively reviewed utilizing the institutional total joint registry. Patients with monomicrobial PJI and two or more positive cultures were considered to have true C. acnes PJI. Patients with polymicrobial infection or with only one positive culture were excluded. This resulted in 35 PJIs (21 hips and 14 knees); the patients’ mean age was 63 years (35 to 84) and 15 (43%) were female. Mean follow-up was five years (1 to 14). Results The median time to positive culture was five days (IQR 5 to 6) and median synovial fluid cell count was 22,583 cells (IQR 15,200 to 53,231). The median ESR was 25 mm/hr (IQR 7 to 37), and CRP was 15 mg/l (IQR 3 to 29). Of the 35 PJIs, 18 (51%) were treated with chronic antibiotic suppression without surgical intervention, and the remainder were treated with two-stage exchange arthroplasty. The two-year survival free of any revision was 94%. Four patients failed treatment due to symptomatic infection, with three treated with two-stage exchange and one treated with irrigation and debridement with modular component exchange for a survival rate of 89% and 83% at two and five years, respectively. Conclusion Laboratory evidence of C. acnes PJI in this cohort was typical compared to more conventional organisms. Cultures grew more quickly than previously thought in patients with C. acnes PJI. Treatment with two-stage exchange or chronic antibiotic suppression alone both had few treatment failures at mid-term follow-up. Cite this article: Bone Joint J 2024;106-B(12):1426–1430.
In‐field prostate cancer recurrence following radical prostatectomy and salvage radiation
Martin, Austin , Britton, Cameron J. , Fadel, Anthony , Ahmed, Mohamed E., Sharma, Vidit , Mynderse, Lance A. , Lomas, Derek J. , Woodrum, David A. , Frendl, Daniel M. , Karnes, Jeffrey , Tollefson, Matthew K. , Kwon, Eugene D., Andrews, Jack R. , Fadel, Anthony , Davis, Brian J. , Mynderse, Lance, Lomas, Derek , Woodrum, David, Karnes, Jeffrey R, Mahmoud, Ahmed , Childs, Daniel S. , Johnson, Geoffrey B.

Mayo Clinic

BJU International | November 30, 2024 | Volume: 135 | Issue: 4 | Pages: 668-674

10.1111/bju.16598 | PMID 39614716 Get It

Objective To define the natural history, patterns of recurrence and treatment modalities for local prostate cancer (PCa) recurrence following radical prostatectomy (RP) and radiation therapy (RT), and to investigate factors that could predict metastasis‐free survival (MFS) in this unique patient population. Methods We queried a prospectively maintained PCa registry to identify men developing in‐field recurrence (IFR) following RP and RT from 2008 to 2021 at a single institution. IFR was defined as biopsy‐proven recurrent PCa or the presence of persistent positron emission tomography‐avid lesions in the prior radiation field without evidence of metastasis. Cox regression was conducted to determine predictors of MFS. Kaplan–Meier methods were used to calculate MFS, cancer‐specific survival (CSS) and overall survival (OS) for patients in three primary therapy categories: cryoablation, androgen deprivation therapy (ADT) alone, and surveillance. Results Of 4575 patients from our registry, 108 (2.3%) with IFR were identified. The median (interquartile range [IQR]) time to IFR from salvage treatment was 78 (50–126) months. A total of 29 patients (26%) were managed with cryoablation, 23 (21%) with ADT, and 28 (25%) with surveillance. The median (IQR) follow‐up was 76 (48–100) months. There were no statistically significant differences in MFS ( P = 0.67) or OS ( P = 0.07) among the three primary treatment cohorts. Patients treated with ADT or cryoablation had longer CSS compared to patients managed with surveillance ( P = 0.047). Conclusions We found that IFR may present years after completion of primary treatment for PCa. While curative management strategies may be attempted, local and distant metastatic recurrence is common and often requires systemic therapy.
Molecular Features of Diffuse Large B‐Cell Lymphoma Associated With Primary Treatment Resistance
Bock, Allison M. , Wenzl, Kerstin , Stokes, Matthew E. , Hopper, Melissa A. , Dropik, Abigail R. , Sarangi, Vivek, Ortiz, Maria, Huang, Chuican , King, Rebecca L., Ansell, Stephen M., Gandhi, Anita K. , Nowakowski, Grzegorz S. , Novak, Anne J. , Hopper, Melissa A , Dropik, Abigail R , Wang, Yucai , Witzig, T.E. , Novak, Joseph P. , Krull, Jordan E. , Stong, Nicholas , Maurer, Matthew J. , Farooq, Umar , Wang, Yucai , Witzig, Thomas E. , Ansell, Stephen M. , Habermann, Thomas M. , Cerhan, James R.

Mayo Clinic

Hematological Oncology | November 29, 2024 | Volume: 43 | Issue: 1 | Pages: No page available

10.1002/hon.70006 | PMID 39612356 Get It

ABSTRACTDiffuse large B‐cell lymphoma (DLBCL) patients that fail to achieve a complete metabolic response with frontline immunochemotherapy have a poor prognosis. Genomic profiling has led to a broader understanding of the molecular drivers in DLBCL, but it is unknown how well current classifiers identify patients that will experience primary treatment resistance (PTR). Using whole exome and RNA sequencing data from newly diagnosed DLBCL patients, we evaluated the genomic landscape of PTR and compared it to that of non‐PTR DLBCL. We found a significant increase in the frequency of TP53 (34% vs. 15%, p = 0.005) and ARID1A mutations (21% vs. 7%, p = 0.007) in PTR cases, with pathway analysis further demonstrating a downregulation of TP53 and an increase in chromatin modifying pathways. These results suggest that TP53 and ARID1A may be key mediators of PTR and important pathways contributing to the poor outcomes. We found that the current molecular classifiers were unable to identify PTR cases at diagnosis. However, our newly identified high‐risk signature identified 46% of PTR cases at diagnosis. Overall, these results contribute to our understanding of the genomic landscape of patients with primary treatment resistance.
Chondrosarcoma of the Flat Bones: Differential Survival Between High‐Grade Lesions of the Pelvis and Scapula
Sullivan, Mikaela H. , Broida, Samuel E. , Cleary, Emmett J., Rose, Peter S. , Houdek, Matthew T. , Houdek, Matthew T , Broida, Samuel E

Mayo Clinic

Journal of Surgical Oncology | November 28, 2024 | Volume: 131 | Issue: 5 | Pages: 925-931

10.1002/jso.28023 | PMID 39609948 Get It

ABSTRACT Background Flat bone chondrosarcomas have worse outcomes than extremity tumors, but there is no data directly comparing the different flat bones. The aim of this study was to examine differences in recurrence and survival between pelvic and scapular chondrosarcoma. Methods One hundred and sixty‐nine (42 scapula, 127 pelvic) patients with chondrosarcoma who underwent surgical resection were reviewed. High‐grade tumors were defined as lesions that were Grade 3 or dedifferentiated on surgical pathology. Results Patients with low‐intermediate grade lesions of the scapula were more likely to have positive margins during definitive surgical management (14% vs. 3%, OR 5, 95% CI [1.15, 22.6], p = 0.02), however, this did not translate to differences in recurrence or survival ( p > 0.05). The presence of an associated soft tissue mass in low‐intermediate grade lesions was not associated with increased recurrence. Among high‐grade tumors, patients with scapular lesions had worse DSS (HR 2.99, 95% CI [1.05, 8.51], p = 0.04). One‐ and 2‐year DSS for high‐grade pelvic tumors was 75% and 57%, respectively, and 50% and 33% for scapular tumors. Conclusion Survival for high‐grade chondrosarcoma of the flat bones is poor, particularly for those of the scapula. Despite a higher rate of positive margins for low‐intermediate grade lesions of the scapula, there was no significant difference in survival compared to low‐intermediate grade lesions of the pelvis. Additional studies with larger sample sizes are needed to further elucidate differences between these locations.
Get to know your neighbors with a SNAQ™: A framework for single cell spatial neighborhood analysis in immunohistochemical images
Silver, Aryeh , Chakraborty, Avirup , Pittu, Avinash, Feier, Diana , Anica, Miruna, West, Illeana, Sarkisian, Matthew R. , Deleyrolle, Loic P. , Chakraborty, Avirup , Feier, Diana

Mayo Clinic

Computational and Structural Biotechnology Journal | November 28, 2024 | Volume: 23 | Issue: No issue available | Pages: 4337-4349

10.1016/j.csbj.2024.11.040 | PMID 39697680 Get It